From: Therapeutic opportunities for targeting microRNAs in cancer
microRNA | Disease setting | Targets | Hallmark (s) of cancer |
---|---|---|---|
oncomiRs | |||
miR-17 ~ 92 Family | Lymphoma and some solid tumors [36] | PTEN [37, 38], Bim [7, 37], p21 [40, 41], TSP1 [42], CTGF [42] | Resisting cell death |
Sustaining proliferative signaling, and inducing angiogenesis | |||
miR-21 | Glioblastoma [44], breast, colon, lung, pancreas, prostate, chronic lymphocytic leukaemia, Diffuse Large B-Cell Lymphoma, acute myeloid leukaemia and others [45, 46] | PTEN, p63, PDCD4, and RECK [46] | Sustaining proliferative signaling, resisting cell death, activating invasion and metastasis |
miR-155 | Lymphoma [50, 51], breast, colon, lung, pancreatic, and thyroid cancer [52] | Sustaining proliferative signaling, resisting cell death, activating invasion and metastasis | |
Tumor suppressor miRs | Â | Â | Â |
miR-15a ~ 16-1 | CLL [56], multiple myeloma, mantle cell lymphoma, and prostate cancers [57] | Bcl2, cyclin D1, and WNT3A [59] | Evading growth suppressors, Resisting cell death |
let-7 | Evading growth suppressors | ||
miR-29 Family | Lung cancer, melanoma and myeloid leukemia [75] | CDK6 [70, 71], Ppmid [68], osteonectin [72], Mcl1 [73], Bcl2 [74], DNMT3a [75], and extracellular matrix genes [76]. | Sustaining proliferative signaling, Enabling replicative immortality, Resisting cell death |
miR-34 | Breast, lung, colon, kidney, bladder, pancreatic cancer, and melanoma [84] | Bcl2, cyclin D1, Cyclin E2, CDK4, CDK6, c-Myc , MET, N-Myc, and SIRT1 [78–83] | Resisting cell death, Evading tumor suppressors, Enabling replicative immortality. |
metastamiRs | Â | Â | Â |
miR-200 Family | Activating invasion metastasis | ||
miR-9 | Activating invasion metastasis | ||
miR-31 | Breast cancer [99] | Activating invasion metastasis | |
miR-10b | HOXD10 [102] | Activating invasion metastasis | |
miR-181a | Breast cancer [108] | Activating invasion metastasis |